-
1 Comment
MYOS RENS Technology Inc is currently in a long term uptrend where the price is trading 705.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.2.
MYOS RENS Technology Inc's total revenue rose by 38.6% to $485K since the same quarter in the previous year.
Its net income has increased by 11.5% to $-815K since the same quarter in the previous year.
Finally, its free cash flow grew by 29.4% to $-543K since the same quarter in the previous year.
Based on the above factors, MYOS RENS Technology Inc gets an overall score of 5/5.
| CurrencyCode | USD |
|---|---|
| ISIN | US62857P1084 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | OTCBB |
| Market Cap | 1M |
|---|---|
| PE Ratio | None |
| Target Price | 3.75 |
| Dividend Yield | 0.0% |
| Beta | 1.08 |
MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform. It has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery of compounds and products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MYOS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
